MetaCap

Oric Pharmaceuticals Inc. (ORIC)

NASDAQ: ORICHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.36-0.34 (-4.42%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ORIC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$764.94M
EPS (TTM)
-$1.44
52-week range
7.23 – 14.68
Day range
7.28 – 8.00
Volume / Avg
1.46M / 1.59M
Beta
—

52-week range

$7.23$14.68

ORIC stock today

Oric Pharmaceuticals (ORIC) closed at $7.36 on Nov 20, down 4.42% (-$0.34), versus the S&P 500's 3.70% decline. Shares are 49.9% below their 52-week high of $14.68, set on Aug 19, 2026 and 1.8% above the 52-week low of $7.23, near the bottom of the past year's range. ORIC is down 10.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.7%.

Oric Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Oric Pharmaceuticals

Company profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jacob M. Chacko M.B.A., M.D.
Headquarters
South San Francisco, CA
Employees
111
IPO year
2020

Financial highlights

Full financials

Oric Pharmaceuticals reported a net loss of $129.5 million, compared with a loss of $127.8 million a year earlier. Diluted earnings per share came in at -$1.47.

Oric Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-129.47M$-127.85M$-100.70M$-89.12M$-78.72M
EPS (diluted)$-1.47$-1.83$-1.96$-2.25$-2.07

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$21.71+194.97%

  • Strong buy 2
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $14.00High $27.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.44 vs $-0.41
Surprise
-7.32%

ORIC news

All ORIC news

Oric Pharmaceuticals peers

Health Care sector
ORIC peer companies
CompanyPrice% ChgMarket capCompare
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs ORIC
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs ORIC
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs ORIC
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs ORIC
IVAInventiva S.A. American Depository Shares3.14-8.99%$750.78Mvs ORIC
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs ORIC
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs ORIC
VSTMVerastem Inc.6.33-7.73%$797.67Mvs ORIC

Indexes, lists and sector

Oric Pharmaceuticals stock FAQ

What is Oric Pharmaceuticals's stock price today?

ORIC last traded at $7.36 as of Nov 20, 4:00 PM EST, down 4.42% on the day. Prices are delayed at least 15 minutes.

Who is Oric Pharmaceuticals's CEO?

Dr. Jacob M. Chacko M.B.A., M.D. is the chief executive officer of Oric Pharmaceuticals Inc., which has about 111 employees.

What is the ORIC 52-week high?

The 52-week high for ORIC is $14.68 and the 52-week low is $7.23. The stock is currently 49.9% below its high.

Compare ORIC